Cheap Arthritis Drug Shows Promise Against RSV in Kids

Scientists have discovered that indomethacin, a widely available painkiller used for arthritis, dramatically reduces RSV in human lung cells, offering hope for the first specific treatment against a virus that sends more babies to the hospital than any other illness in America.

Respiratory syncytial virus poses the greatest danger to infants under six months old and adults over 65. While vaccines and preventive antibody drugs exist, doctors currently have no antiviral medication to treat RSV once someone gets infected.

Researchers at Italy's Tor Vergata University tested indomethacin on human airway cells infected with RSV. The drug stopped the virus from multiplying at very low doses across all cell types tested, including cells from the larynx, bronchus, and lungs.

The timing matters. Indomethacin only worked after RSV had already entered cells, interfering with a key protein the virus needs to spread. Giving the drug before infection or during initial attachment had no effect.

Here's what makes the finding especially interesting: the researchers also tested aspirin, which works almost identically to indomethacin as a painkiller. Aspirin had zero effect on RSV, proving that indomethacin's antiviral power is separate from its anti-inflammatory properties.

The drug already has a safety track record in vulnerable patients. Doctors routinely give indomethacin to premature babies with certain heart conditions, and it's generally very safe for short-term use. Higher doses over longer periods can cause kidney issues or digestive problems, but those risks are manageable.

Previous research showed indomethacin fights several other viruses, including those behind SARS and COVID-19. In a small COVID trial, patients taking indomethacin recovered twice as fast as those using acetaminophen.

Dr. Amy Edwards, a pediatric infectious disease specialist at University Hospitals in Ohio not involved in the study, emphasized caution. Lab results don't always translate to real-world medicine, she explained, though studies like this are crucial first steps toward identifying treatments worth testing in clinical trials.

Dr. Aaron Glatt, chief of infectious diseases at Mount Sinai South Nassau, agreed the findings won't change patient care tomorrow. But he called the research "of potential great interest" for future treatment development.

Why This Inspires

What makes this discovery so encouraging is the drug's accessibility. Indomethacin is already cheap, widely available, and proven safe in the very populations most vulnerable to severe RSV. If clinical trials confirm what researchers saw in the lab, hospitals could quickly add an effective RSV treatment to their toolkits without waiting years for new drug development or facing prohibitive costs that keep medicines out of reach.

The research team plans to dig deeper into exactly how indomethacin blocks viral replication and to move toward human trials.